There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Genelux Corp. (GNLX – Research Report) and Calliditas Therapeutics (CALT – Research Report) with bullish sentiments.
Genelux Corp. (GNLX)
In a report released today, Emily Bodnar from H.C. Wainwright initiated coverage with a Buy rating on Genelux Corp. and a price target of $35.00. The company’s shares closed last Friday at $11.10, close to its 52-week low of $5.35.
According to TipRanks.com, Bodnar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Genelux Corp. has an analyst consensus of Strong Buy, with a price target consensus of $33.75, which is a 198.9% upside from current levels. In a report issued on November 15, Maxim Group also maintained a Buy rating on the stock with a $40.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Calliditas Therapeutics (CALT)
H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Calliditas Therapeutics today and set a price target of $50.00. The company’s shares closed last Friday at $18.70.
According to TipRanks.com, CFA has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Calliditas Therapeutics is a Strong Buy with an average price target of $36.11.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GNLX:
